In Brief: SmithKline Beecham/TheraTech Androderm
Executive Summary
SmithKline Beecham/TheraTech Androderm: FDA approves 5 mg daily testosterone patch for the treatment of male hypogonadism on May 2. Androderm, which TheraTech manufactures for SmithKline, was previously marketed as a two-patch, 2.5 mg formulation...